Company intelligence / Profile preview

EnduRx Pharmaceuticals

Tucson, Arizona, United Statesendurxpharm.com ↗

Ownership: Private
Employees: ~3
Development stage: Preclinical

Overview

EnduRx has demonstrated significant tumor volume reductions—and sometimes complete elimination—in preclinical models using its peptide-directed nanoparticle technology. The company has received grant funding to advance its lead program toward IND-enabling studies, with ongoing collaborations to further validate the approach.

Therapeutic areas: OncologyCardiovascularOther
Modalities: Polymeric nanoparticles (peptide-directed)Macromolecule-based drug delivery systemsChemical drugs
Industry: Biotech

Drug pipeline

4 assets

ERXC102

Preclinical

3 more assets in the full pipeline.

Request access →

Partnerships

Collaboration with MD Anderson Cancer Center on triple-negative breast cancer program funded by Department of Defense grant

Beyond the preview

Go deeper on EnduRx Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EnduRx Pharmaceuticals.

Explore the full profile